Anixa Biosciences Inc (ANIX)
Data as of , from SEC Form 4 filings.
See up to 3 months of ANIX. The 7-day demo opens the 1M and 3M ranges and puts ANIX on your watchlist.
Start 7-day demoLatest ANIX insider trades
- Michael Catelani - OfficerOpen-market purchase$16K
Amit Kumar
About Anixa Biosciences Inc (ANIX)
Anixa Biosciences Inc is a biotechnology company developing therapies and vaccines focused on critical unmet needs in oncology. Its operations are organized into reportable segments comprising Cancer Vaccines, CAR-T Therapies, and Other. The Cancer Vaccines segment involves vaccines to treat and prevent breast and ovarian cancer, as well as additional cancer vaccines targeting intractable cancers, including high-incidence malignancies in lung, colon, and prostate. The CAR-T Therapies segment involves the development of liraltagene autoleucel (lira-cel), an ovarian cancer immunotherapy using chimeric endocrine receptor-T cell technology, developed at its subsidiary, Certainty Therapeutics, Inc. The Other segment consists of legacy operations, including limited patent licensing activities.
- SAN JOSE, CA
- 4
- 1983
- XNAS
ANIX Form 4 activity by transaction type, last 90 days
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market purchase | 12 | 114,536 | $335K |
| Option exercise | 2 | 12,000 | |
| Tax withholding / forfeiture | 1 | 5,428 |
Dollar totals cover purchases and sales only (codes P and S). Grants, option exercises, gifts and tax withholding are counted in shares, because none of them is a trade at a market price.
ANIX insider transactions (Form 4)
332 Form 4 filings on record, the earliest from Oct 23, 2024, newest first. Filing history page 2 of 2.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Amit Kumar - Officer | Open-market purchase | Common Stock | 10,000 | $2.85 | $29K | |
| Lewis H. Titterton Jr. - Director | Option exercise | Common Stock | 16,000 | $2.58 | $41K | |
| Lewis H. Titterton Jr. - Director | Option exercise | Employee Stock Option | 16,000 | $0.00 | - |
ANIX insider trading FAQ
What is the latest insider trade for ANIX?
Anixa Biosciences Inc (ANIX) had 13 insider filings in the last 90 days, with the most recent on 2026-09-30. The full record for ANIX runs to 32 Form 4 filings, the earliest from 2024-10-23. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
How many insiders are buying ANIX stock?
12 insider purchases of ANIX were filed in the last 90 days, totaling $335K.
How many insiders are selling ANIX stock?
No insider sales of ANIX were filed in the last 90 days.
Where can I see ANIX SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page collects ANIX Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
More Health Care companies with insider activity
Recent insider filings
10The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.
- - Michael Catelani view on EDGAR
- - Amit Kumar view on EDGAR
- - Arnold M. Baskies view on EDGAR
- - Lewis H. Titterton Jr. view on EDGAR
- - Amit Kumar view on EDGAR
- - Lewis H. Titterton Jr. view on EDGAR
- - Amit Kumar view on EDGAR
- - Amit Kumar view on EDGAR
- - Arnold M. Baskies view on EDGAR
Related companies with recent insider activity
Learn more
- How to read insider buying signals
- What an open-market purchase by an insider can and cannot tell you.
- Insider activity in Health Care
- Where ANIX's peers are being bought and sold.
- Every recent Form 4
- The market-wide feed, updated as filings arrive from SEC EDGAR.
Follow ANIX with a 7-day demo
- ANIX on your watchlist
- Every ANIX Form 4 filing on record
- Up to 3 months of ANIX price history
- The daily trading plan of ranked insider buys, on a delay, with the plan archive
